Recently, a meta-analysis of randomized controlled trials showed that GLP-1 RAs also significantly reduced adverse kidney events and renal failure, which make GLP-1 RAs an optimal treatment choice of DKD [32]. This evidence concerns the gene GLP1R and Renal insufficiency.